Please login to the form below

Not currently logged in
Email:
Password:

The Sudler London Award for Excellence in Mature Brand Revitalisation

Sponsored by

Finalist

AmBisome – Winning the Battle for Hearts and Minds

Gilead in association with Langland


Summary of work

Effective clinical decision-making is vital when managing invasive fungal infections. The immuno-compromised, including cancer and intensive care patients, can succumb to infection and rapidly deteriorate. Delaying or choosing an inappropriate treatment option can be fatal. 

Launched in 1990, Gilead’s AmBisome (liposomal amphotericin B) became the gold standard within the anti-fungal category. However during the following 20 years, the landscape changed. Competitor brands aligned themselves to the two major pathogen classes, effectively bisecting the market and niching AmBisome.

With AmBisome’s market share declining year-on-year, the brief to the 2010 global brand team was simple – keep it ticking over. 

Instead, with cross-functional team-work and customer engagement, AmBisome was cleverly repositioned. Despite being in a functional-led category, the brand was aligned to a key emotional driver, realised through powerful creative work. Enabling the brand to challenge customers’ mindsets. Coupled with a strong clinical rationale, the campaign targeted diversified key segments and delivered consistently through innovative tactics. 

Effective affiliate management led to excellent local implementation. Following years of declining performance, AmBisome, two decades post-launch, demonstrated market share growth. Internal attitudes were transformed and the campaign became a catalyst for a new chapter in its life cycle. 

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics